No assignee for this patent application has been made.
News editors obtained the following quote from the background information supplied by the inventors: "The present invention relates to the fine and superfine particle of Prussian Blue type complex with nanometer-scale size. Metal-complexes consisting of particular metals and particular coordination molecules show various properties depending on the combination of the kind of metal and kind of coordination molecules. In the present invention the crystal of Prussian Blue complexes includes certain modifications, such as substitution or defects of the hexacyano-metallic group, the transition metals forming Prussian Blue-like structures and intercalation of various ions in the crystals, and water.
"Iron-containing nanoparticles have found widespread biomedical applications such as magnetic-field guided drug delivery, hyperthermia for cancer treatment, and medical imaging (e.g. magnetic resonance imaging (MRI)). Most frequently iron oxide based nanoparticles are applied. There are many forms of iron oxide nanoparticles used in academic and clinical applications which can be divided into three categories: oral Superparamagnetic Iron Oxide (SPIO) (size: 3500 nm-200 nm), standard SPIO (SSPIO) (size: 200-50 nm); and ultrasmall SPIO (USPIO) (size:
"WO 96/04017 discloses an iron-containing nanoparticle with modular structure (core, polymer coat and targeting polymer coat). The disclosure focuses on MRI applications of iron- and other metal-containing nanoparticles. WO 96/03653 discloses a superparamagnetic nanoparticle built up from one or aggregated one-domain nanoparticle containing iron-oxide and iron-hydroxide, and having a particle size in the 3-50 nm range.
"WO 2009/136764 discloses a dual modality PET/MRI contrast material the core of which is built of iron-oxide or metallic alloy.
"Prussian Blue is a dark blue micro-crystalline pigment, one of the first synthetic dyes. The Prussian Blue dye is a common histopathology (ex vivo) stain, used to detect the presence of iron in biopsy specimens, such as in bone marrow samples. Iron deposits in tissue are visualized as blue or purple deposits of Prussian Blue dye formed by a specific histochemical reaction in situ.
"In the last decade some research groups produced Prussian Blue nanoparticles which were tested then as potential MRI contrast agents and drug delivery systems. In order for Prussian Blue to be successfully utilized as drug delivery agents they must be capable of crossing the plasma membrane. To study intracellular uptake of the Prussian Blue particles the surfaces were functionalized with small molecules, or an anti-tumor agent for instance doxorubicin. The functionalized Prussian Blue particles with both MRI contrast and drug delivery capabilities may become powerful dual agents for simultaneous cancer treatment and assessment of treatment effectiveness.
"Finding scalable manufacturing processes of nanoparticles is very important for practical application of Prussian Blue and its analogues. There have been a few reports of the method to produce such nanoparticles. The majority of those, however, do not suit for inexpensive and simple mass production because of the complexity of the synthesizing process (
"The cytotoxicity of Prussian Blue nanoparticles is a more crucial problem compared with other nanoparticles by reason of cyanide content, therefore it was assessed and the results show that the cyanide groups do not pose any toxicity problem. In addition, the nanoparticle is very stable hereby no toxic effects of freely available cyanide groups can be expected.
"Prussian Blue's ability to incorporate mono-cations makes it useful as a sequestering agent for certain heavy metal poisons.
"The present invention relates to metal intercalation ability of Prussian Blue which allows various applications in multimodal imaging and in the therapy."
As a supplement to the background information on this patent application, NewsRx correspondents also obtained the inventors' summary information for this patent application: "The present invention relates to Prussian Blue based nanoparticles that have a modular structure, and the use thereof for diagnostic and therapeutic purposes. The nanoparticles according to the invention comprise a Prussian Blue based metal core doped with metal isotope(s) and an organic biocompatible coating. The nanoparticles according to the invention can be used as contrast material for detection with different imaging modalities such as MRI, X-ray Computed Tomography (CT), Single Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET) or optical imaging (OI) methods during clinical, in vivo, or in vitro studies. Furthermore, the nanoparticles according to the invention can be used for therapeutic purposes.
BRIEF DESCRIPTION OF DRAWINGS
"FIG. 1 shows a Prussian Blue or analogue nanoparticle with primary metal coat and optionally secondary associated biomaterials.
"FIG. 2 shows a Prussian Blue or analogue nanoparticle with mixed position metal coat and optionally secondary associated biomaterials.
"FIG. 3 shows a Prussian Blue or analogue nanoparticle with mixed position metal coat and optionally secondary associated biomaterials which could chelate different ions or metals."
For additional information on this patent application, see: Mathe, Domokos; Szigeti, Krisztian. Prussian Blue Based Nanoparticle as Multimodal Imaging Contrast Material. Filed
Keywords for this news article include: Patents, Therapy, Chemicals, Chemistry, Treatment, Legal Issues, Prussian Blue, Drug Delivery Systems.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC
Most Popular Stories
- Chinese May Have Spotted Malaysia Airlines Debris
- 3 Shot Dead in Venezuela Unrest
- Why Buffett Bets Big on Green Energy
- Better Pay Means Bigger Profits: Strategist
- Banks Buying Little From Minority Firms: Study
- Several Texas Cities Top Job Search List
- G7 Presses Russia to Pull Troops Out of Crimea
- Obama's 'Between Two Ferns' Appearance Has Conservatives Upset
- Senate Committee OKs Bill to Sanction Russia
- Wall Street Rally Heads Off 3rd Day of Decline